BioTelemetry (BioTelemetry) Risk Assessment

View and export this data going back to 2008. Start your Free Trial

What is BioTelemetry Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of BioTelemetry is: No Data: Cannot be evaluated.

Competitive Comparison of BioTelemetry's Risk Assessment

For the Diagnostics & Research subindustry, BioTelemetry's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioTelemetry's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BioTelemetry's Risk Assessment distribution charts can be found below:

* The bar in red indicates where BioTelemetry's Risk Assessment falls into.

BioTelemetry (NAS:BEAT) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

BioTelemetry Risk Assessment Related Terms

Thank you for viewing the detailed overview of BioTelemetry's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

BioTelemetry (BioTelemetry) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioTelemetry Inc (NAS:BEAT) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

1000 Cedar Hollow Road, Suite 102, Malvern, PA, USA, 19355

Website

https://www.gobio.com

BioTelemetry Inc provides monitoring services and digital population health management for healthcare providers, medical device manufacturing, and centralized core laboratory services for clinical research. It operates under healthcare, technology, and research segments. The Healthcare segment is focused on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. The Research segment is engaged in central core laboratory services providing cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials and the Technology segment, focuses on the development, manufacturing, testing, and marketing of cardiovascular and blood glucose monitoring devices to medical companies, clinics and hospitals.

Executives

Kirk E Gorman	director	367 SOUTH GULPH ROAD, KING PRUSSIA PA 19406
Stephen Rietiker	director	C/O BIOTELEMETRY, INC., 1000 CEDAR HOLLOW RD. SUITE 102, MALVERN PA 19355
Tiffany Olson	director	C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Joseph A. Frick	director	ONE COMMERCE SQUARE 2005 MARKET ST., SUITE 3300 19103 PR 19073
Laura N. Dietch	director	1000 CEDAR HOLLOW RD. SUITE 102 MALVERN PA 19355
Anthony James Conti	director	76 GOLFVIEW DRIVE, IVYLAND PA 18974
Rebecca W Rimel	director	345 PARK AVENUE, NEW YORK NY 10154
Robert J. Rubin	director	7901 SPRINGER ROAD, BETHESDA MD 20817
Hill Colin	director	196 BROADWAY CAMBRIDGE MA 02139
Andrei G Stoica	officer: SVP & CTO	1000 CEDAR HOLLOW ROAD, MALVERN PA 19355
Joseph H Capper	director, officer: President & CEO	BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Manish Wadhwa	officer: SVP & CMO	1000 CEDAR HOLLOW ROAD MALVERN PA 19355
Fred Broadway	officer: President BioTel Heart	BIOTELEMETRY, INC. 1000 CEDAR HOLLOW ROAD, #102 MALVERN PA 19355
Daniel Wisniewski	officer: SVP, Technical Operations	BIOTELEMETRY, INC. 1000 CEDAR HOLLOW ROAD, #102 MALVERN PA 19355
Heather C Getz	officer: EVP, CFO & CAO	BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355